Dear Ms. Wambach:

Please refer to your supplemental new drug application dated February 24, 2009, received February 25, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Viread® (tenofovir disoproxil fumarate).

We acknowledge receipt of your submission dated October 16, 2009.

This supplemental new drug application provides for labeling revisions to the WARNINGS AND PRECAUTIONS, New Onset or Worsening of Renal Impairment; ADVERSE REACTIONS, Post Marketing Experience; CLINICAL PHARMACOLOGY, Microbiology and PATIENT COUNSELING INFORMATION, FDA-Approved Patient Labeling sections of the Full Prescribing Information.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed upon labeling text.

**CONTENT OF LABELING**

Within 14 days from the date of this letter, please amend all pending supplemental applications for this NDA, including pending "Changes Being Effected" (CBE) supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format that includes the changes approved in this supplemental application.

**LABELING**

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert).
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Carrie Ceresa, Pharm D., MPH, Regulatory Project Manager, at (301) 796-4108.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure (clean copy of approved labels)
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-21356</td>
<td>SUPPL-28</td>
<td>GILEAD SCIENCES INC</td>
<td>VIREAD(TENOFOVIR DISOPROXIL FUMARATE)300</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
11/10/2009